#United States #Boston #AI Growth #Biotech Leaders #Cellular Intelligence

Cellular Intelligence Expands Leadership Team with New Appointments

In a significant move towards enhancing its capabilities, Cellular Intelligence, an AI-driven company focused on developing a universal foundation model for cell signaling, has announced the strategic addition of Jonathan Alspaugh as Chief Strategy Officer and Adam Weinroth as Chief Marketing Officer.

These appointments are pivotal as Cellular Intelligence gears up for its next growth phase, marking an important inflection point in its mission to interpret cellular communication language, thereby accelerating novel therapeutic applications. Alspaugh brings with him more than 15 years of expertise in biopharmaceutical strategies, finance, and operations, while Weinroth contributes over two decades in scaling AI and deep-tech platforms.

The announcement follows Cellular Intelligence's recent acquisition of STEM-PD, a therapy program for Parkinson's disease from Novo Nordisk, positioning it to create a new path for patient access. This program will not only test the company’s technology but is also expected to yield valuable clinical and production insights that will inform future developments. The integration of STEM-PD with Cellular Intelligence's existing technology aims to streamline therapeutic manufacturing and establish a robust data loop, where clinical experiences directly feedback into their models.

Micha Breakstone, Ph.D., Co-Founder and CEO, expressed the company's long-standing vision for Cellular Intelligence: “We founded Cellular Intelligence on the belief that decoding cellular communication is key to shaping a future in which biology transforms from unpredictability to precision engineering.” He emphasized that both Alspaugh and Weinroth are well-equipped to refine the firm’s business strategy and advance its scientific pursuits.

Alspaugh previously held senior roles at RyCarma Therapeutics and Aeglea BioTherapeutics, where he successfully led significant strategic initiatives, including mergers and acquisitions. His extensive background in investment banking at Evercore further bolsters his capacity to guide Cellular Intelligence through complex financial landscapes. With advanced degrees from prominent institutions, he combines technical expertise with financial acumen, preparing him to significantly impact the organization's strategy and growth.

Commenting on his new role, Alspaugh noted, “Data serves as a vital resource in AI initiatives. Cellular Intelligence collects invaluable cell signaling data, allowing us to train our model effectively at an unparalleled scale. Our clinical programs also serve as a rich data source, igniting innovative developments in biology and drug creation.”

Weinroth joined Cellular Intelligence after building a successful marketing strategy for Form Bio, a genetic medicine platform. His experience in various leading tech companies has solidified his reputation for establishing market position and brand identity within competitive sectors. He boasts two degrees from the University of Texas at Austin that have prepared him for trailblazing marketing efforts.

Expressing his excitement about joining Cellular Intelligence, Weinroth stated, “Biology is on the brink of a transformative era, and our technology is positioned to advance this frontier. The caliber of the team and our ambitious agenda cements our standing as a critical player in the life sciences today.”

As Cellular Intelligence embarks on this enhanced journey, the leadership of Alspaugh and Weinroth is expected to play a crucial role in navigating the complex landscape of biotech development. With their depths of experience and alignment with the company’s vision, they are set to create substantial value not just for Cellular Intelligence but for the broader scientific community as well.

To learn more about Cellular Intelligence and its groundbreaking work in the field of cell signaling, visit www.cellularintelligence.com.

About Cellular Intelligence

Founded with the aim of transforming biology into a precise engineering discipline, Cellular Intelligence is at the forefront of AI technology, holding global rights to the investigational Phase 2-ready cell therapy for Parkinson's disease known as STEM-PD. This therapy has received FDA Fast Track designation, emphasizing its potential impact. The company's team, which includes esteemed professionals from top institutions, has raised over $70 million from notable investors, including Khosla Ventures and Chan Zuckerberg Initiative, marking it as a promising entity within the biotech industry.